247 related articles for article (PubMed ID: 23759003)
21. Words of wisdom: Re: Comparative effectiveness of alternative prostate-specific antigen-based prostate cancer screening strategies: model estimates of potential benefits and harms.
Vickers A
Eur Urol; 2013 Oct; 64(4):682-3. PubMed ID: 23998500
[No Abstract] [Full Text] [Related]
22. Early detection of prostate cancer.
Taneja SS
Urol Clin North Am; 2014 May; 41(2):xi-xii. PubMed ID: 24725495
[No Abstract] [Full Text] [Related]
23. Prostate cancer screening "reloaded".
Gomella LG
Can J Urol; 2010 Apr; 17(2):5057. PubMed ID: 20398441
[No Abstract] [Full Text] [Related]
24. Prostate-specific antigen dynamics and prostate cancer diagnosis.
Bartoletti R
Eur Urol; 2009 Nov; 56(5):761-2; discussion 763. PubMed ID: 19665286
[No Abstract] [Full Text] [Related]
25. Early detection of prostate cancer: can we have our cake and eat it too?
Masterson TA; Cary C; Cheng L
Expert Rev Anticancer Ther; 2016; 16(3):247-9. PubMed ID: 26760708
[No Abstract] [Full Text] [Related]
26. Screening for prostate cancer remains controversial.
Neal DE; Donovan JL; Martin RM; Hamdy FC
Lancet; 2009 Oct; 374(9700):1482-3. PubMed ID: 19664817
[No Abstract] [Full Text] [Related]
27. Prostate cancer screening.
Eastham J
Investig Clin Urol; 2017 Jul; 58(4):217-219. PubMed ID: 28681029
[No Abstract] [Full Text] [Related]
28. Prostate-specific antigen (PSA). A tissue-specific and sensitive tumor marker.
Mulders TM; Bruning PF; Bonfrer JM
Eur J Surg Oncol; 1990 Feb; 16(1):37-41. PubMed ID: 1689677
[TBL] [Abstract][Full Text] [Related]
29. [Detection of cancer of the prostate. A study of 600 cases].
Teillac P; Bron J; Tobolski F; Cussenot O; Lesourd A; Leroy M; Toubert ME; Brocheriou C; Laval-Jeantet M; Le Duc A
Ann Urol (Paris); 1990; 24(1):37-41. PubMed ID: 1690963
[TBL] [Abstract][Full Text] [Related]
30. The "hook effect": high concentrations of prostate-specific antigen giving artifactually low values on one-step immunoassay.
Wolf BA; Garrett NC; Nahm MH
N Engl J Med; 1989 Jun; 320(26):1755-6. PubMed ID: 2471931
[No Abstract] [Full Text] [Related]
31. Refining the assessment of the sensitivity and specificity of diagnostic tests, with applications to prostate cancer screening and non-small cell lung cancer staging.
Berger VW; Semanick L
Rev Panam Salud Publica; 2005 Jul; 18(1):64-70. PubMed ID: 16105328
[No Abstract] [Full Text] [Related]
32. Is prostate cancer screening responsible for the negative results of prostate cancer treatment trials?
Prasad V
Med Hypotheses; 2016 Aug; 93():71-3. PubMed ID: 27372859
[TBL] [Abstract][Full Text] [Related]
33. Screening for prostate cancer: PSA blood test, rectal examination, and ultrasound.
Moore S; Kuhrik M; Kuhrik N; Shea L
Urol Nurs; 1992 Sep; 12(3):106-7. PubMed ID: 1382318
[No Abstract] [Full Text] [Related]
34. Prostate-specific antigen tests and prostate cancer screening: an update for primary care physicians.
Kell JS
Can J Urol; 2010 Feb; 17 Suppl 1():18-25. PubMed ID: 20170597
[TBL] [Abstract][Full Text] [Related]
35. Serum prostate-specific antigen for the early detection of prostate cancer: always, never, or only sometimes?
Carroll PR; Whitson JM; Cooperberg MR
J Clin Oncol; 2011 Feb; 29(4):345-7. PubMed ID: 21189396
[No Abstract] [Full Text] [Related]
36. Correlation between stage shift and differences in mortality in the European Randomised study of Screening for Prostate Cancer (ERSPC).
Bokhorst LP; Zappa M; Carlsson SV; Kwiatkowski M; Denis L; Paez A; Hugosson J; Moss S; Auvinen A; Roobol MJ
BJU Int; 2016 Nov; 118(5):677-680. PubMed ID: 27104278
[TBL] [Abstract][Full Text] [Related]
37. Understanding the study of 21-year follow-up results of the Rotterdam section of the European Randomized Study of Screening for Prostate Cancer.
Nguyen D; Ho L; Nguyen S
World J Urol; 2023 Dec; 42(1):3. PubMed ID: 38133690
[No Abstract] [Full Text] [Related]
38. The need for active surveillance for low risk prostate cancer.
Drost FH; Roobol MJ
Expert Rev Anticancer Ther; 2017 Jun; 17(6):487-489. PubMed ID: 28406334
[No Abstract] [Full Text] [Related]
39. The Roles of Providers and Patients in the Overuse of Prostate-Specific Antigen Screening in the United States.
Guo F; He D
Ann Intern Med; 2015 Oct; 163(8):650-1. PubMed ID: 26502132
[No Abstract] [Full Text] [Related]
40. Prostatic-specific antigen helps establish origin of certain tumors.
JAMA; 1981 Jun; 245(23):2377. PubMed ID: 6164803
[No Abstract] [Full Text] [Related]
[Previous] [Next] [New Search]
